Released: 4-Apr-2008 1:00 PM EDT
University of Colorado Cancer Center Celebrates 20 Years
University of Colorado Cancer Center

Twenty years after opening its doors as the Rocky Mountain region's only National Cancer Institute-designated cancer center, the University of Colorado Cancer Center has become one of the nation's premier institutions for cancer research, education, patient care and outreach.

Released: 16-Jan-2013 9:50 PM EST
Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
University of Colorado Cancer Center

Cancer researchers are increasingly aware that in addition to genetic mutations in a cancer itself, characteristics of the surrounding tissue can promote or suppress tumor growth. One of these important tissue characteristics is inflammation – most cancers prosper in and attach to inflamed tissue and so many cancers have developed ways to create it.

Released: 24-Jan-2013 11:50 AM EST
Planning for Bacteria in Cancer Patients May Help Hospitals Fight Infections
University of Colorado Cancer Center

What cancerous conditions lead to what kinds of bacterial infections? If doctors knew, they could predict which patients would likely benefit from pre-treatment with certain kinds of antibiotics. A University of Colorado Cancer Center study shows the answer: E. coli and Klebsiella pneumoniae are especially prevalent in patients with lung and GI cancers, more so for Klebsiella if these patients have been treated previously with aminopenicillins.

Released: 31-Jan-2013 11:45 AM EST
Silibinin, Found in Milk Thistle, Protects Against UV-Induced Skin Cancer
University of Colorado Cancer Center

A pair of University of Colorado Cancer Center studies published this month show that the milk thistle extract, silibinin, kills skin cells mutated by UVA radiation and protects against damage by UVB radiation - thus protecting against UV-induced skin cancer and photo-aging.

Released: 8-Feb-2013 9:50 AM EST
Long-Term Side-Effects of New, Targeted Therapies in Pediatric Cancer Patients
University of Colorado Cancer Center

A University of Colorado Cancer Center review published this week in the journal Lancet Oncology describes possible long-term side-effects of new, targeted therapies in pediatric cancer patients: what we don’t know may hurt us.

Released: 13-Feb-2013 1:50 PM EST
Problem-Solving Training Helps Mothers Cope with Child’s Cancer Diagnosis
University of Colorado Cancer Center

A multi-site clinical trial including the University of Colorado Cancer Center shows that the benefit of Bright IDEAS problem-solving skills training goes beyond teaching parents to navigate the complex medical, educational, and other systems that accompany a child’s diagnosis of cancer – the training also leads to durable reduction in mothers’ levels of anxiety and symptoms of posttraumatic stress, and improves overall coping with a child’s illness.

Released: 20-Feb-2013 12:00 PM EST
A Diet of Resistant Starch Helps the Body Resist Colorectal Cancer
University of Colorado Cancer Center

A University of Colorado Cancer Center review published in this month’s issue of the journal Current Opinion in Gastroenterology shows that resistant starch also helps the body resist colorectal cancer through mechanisms including killing pre-cancerous cells and reducing inflammation that can otherwise promote cancer.

Released: 23-Jul-2013 2:15 PM EDT
Pathways Activated in Most K9 Bone Tumors not Driving the Worst Bone Tumors
University of Colorado Cancer Center

CU Cancer Center and CSU Flint Animal Cancer Center study shows NOTCH signaling elevated in K9 osteosarcoma, but aspects of Notch signaling noticeably deactivated in the worst cancers.

Released: 8-Aug-2013 5:45 PM EDT
With Early, Obvious Benefit of a Targeted Cancer Drug, Should Expensive Clinical Testing Continue?
University of Colorado Cancer Center

Study: If the science behind a drug shows it to be rationally targeted at a cancer-causing genetic mutation, and if early clinical trials show the drug is safe and happens to be especially effective, should the drug be held to the same time-consuming and expensive testing standards of traditional chemotherapies? Or is the clinical trials process a relic from the time of earlier, highly toxic therapies?

Released: 12-Aug-2013 12:20 PM EDT
Perception of Fertility Affects Quality of Life in Young, Female Cancer Survivors
University of Colorado Cancer Center

A recently published CU Cancer Center study shows that beyond the fact of fertility, a young woman's perception of fertility based on regular menstrual cycles after cancer treatment affects her quality of life long after treatment ends.

Released: 20-Aug-2013 1:45 PM EDT
Chromosome 21 Abnormality Tells Oncologists to Treat Pediatric ALL More Aggressively
University of Colorado Cancer Center

A recent study by members of the Children’s Oncology Group reports results of a large trial showing that children whose leukemia cells have amplification of a portion of chromosome 21 may require more aggressive treatment for Acute Lymphoblastic Leukemia (ALL) than children without this gene amplification.

Released: 26-Aug-2013 12:00 PM EDT
Wait Times Up 78 Percent at V.A. Hospitals for Colorectal Cancer Procedures
University of Colorado Cancer Center

Study shows that wait times for cancer care at V.A. hospitals jumped 78 percent from 1998-2008, but is more careful care worth the wait?

Released: 10-Sep-2013 11:00 AM EDT
Redefining the Criteria for ALK Positive Lung Cancer
University of Colorado Cancer Center

A University of Colorado Cancer Center study published today in the journal Cancer shows that the current criteria used to match lung cancers with the drug crizotinib may miss some patients who could benefit from the drug.

Released: 1-Oct-2013 4:00 PM EDT
$5.9M Grant Adds Androgen Receptor as a New Driver and Target in Breast Cancer
University of Colorado Cancer Center

A decade of work at the University of Colorado Cancer Center puts androgen alongside estrogen, progesterone and HER2 as a major cause of breast cancer.

Released: 23-Oct-2013 5:00 PM EDT
Metformin for Breast Cancer Less Effective at Higher Glucose Concentrations
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that breast cancer cell growth, motility and aggression is promoted by excess glucose, as experienced by patients with diabetes and metabolic syndrome. Patients with high glucose may require higher doses of the drug metformin to achieve the same anti-cancer activity as patients with normal glucose levels.

Released: 28-Oct-2013 4:40 PM EDT
Researchers Detail Possible Resistance Mechanisms of Colorectal Cancer to Bevacizumab (Avastin)
University of Colorado Cancer Center

A University of Colorado Cancer Center study published in the journal PLoS One shows that when colorectal cancer is targeted by the drug bevacizumab (Avastin), tumors may switch dependence from VEGF-A, which is targeted by the drug, to related growth factors in including VEGF-C, VEGF-D and placental growth factor. This change to new growth-factor dependence may allow colorectal cancer to push past bevacizumab’s blockage of VEGF-A to continue to drive tumor growth.

Released: 31-Oct-2013 4:30 PM EDT
Largest Ever Study of Male Breast Cancer Treatment Shows More Mastectomy, Less Radiation Than in Female Disease
University of Colorado Cancer Center

University of Colorado Cancer Center investigator, Rachel Rabinovitch, MD, shows that mastectomy is more used and radiation is less used in male compared to female breast cancer.

Released: 12-Nov-2013 11:00 AM EST
Balloon Mis-Positioning During Prostate Cancer Treatment Could Affect Success of Radiation Delivery
University of Colorado Cancer Center

Moyed Miften, PhD, and CU Cancer Center colleagues show that mis-positioning of endorectal balloon during prostate cancer radiation may affect treatment success

Released: 14-Nov-2013 10:00 AM EST
JAMA Dermatology: Social Media Brings Academic Journals to General Readers
University of Colorado Cancer Center

"If a journal wants to educate people, this is a way to do it," says Robert Dellavalle, MD, PhD, MSPH, investigator at the CU Cancer Center and associate professor of dermatology at the University of Colorado School of Medicine.

Released: 20-Nov-2013 5:00 PM EST
New Crizotinib Side-Effect: Reduced Measures of Kidney Function During Treatment (Recovery After)
University of Colorado Cancer Center

A University of Colorado Cancer Center study published today in the journal Cancer shows that using crizotinib to treat ALK positive non-small cell lung cancer (NSCLC) appears to reduce kidney function when assessed by one of the most commonly used clinical methods.

Released: 4-Dec-2013 4:00 PM EST
Active Component of Grape Seed Extract Effective Against Cancer Cells
University of Colorado Cancer Center

Controlled, lab studies of grape seed extract (GSE) show anti-cancer activity without toxicity to healthy cells

Released: 5-Dec-2013 1:00 PM EST
CARING Criteria Shows 1 Year Death Risk at Time of Hospital Admission
University of Colorado Cancer Center

New tool allows doctors to recognize patients at highest mortality risk, matching treatments to values and health goals.

Released: 17-Dec-2013 12:55 PM EST
Study Finds Known Lung Cancer Oncogenes ALK and ROS1 Also Drive Colorectal Cancer
University of Colorado Cancer Center

A University of Colorado Cancer Center study shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.

Released: 17-Dec-2013 3:00 PM EST
Different Parents, Different Children: Muscle-Invasive and Non-Muscle Invasive Bladder Cancers Arise From Different Stem Cells
University of Colorado Cancer Center

A CU Cancer Center study published today in the journal Stem Cells shows that progenitor cells that create dangerous, muscle-invasive bladder cancer are different than the progenitor cells that create non-muscle invasive bladder cancer. Though these two cancers grow at the same site, they are different diseases.

Released: 15-Jan-2014 3:00 PM EST
Phase II Trial of Bevacizumab (Avastin) in Locally Advanced Cervical Cancer "Promising"
University of Colorado Cancer Center

Addition of Bevacizumab to the existing standard of care was safe and showed promising overall results. The 2- and 3- year overall survival rates were 89.8 percent and 80.2 percent, respectively.

Released: 21-Jan-2014 12:15 PM EST
Possible New Druggable Target in Ewing’s Sarcoma
University of Colorado Cancer Center

A University of Colorado Cancer Center study, recently published in the journal Oncogene, shows that downstream from the oncogenic fusion of genes EWS with FLI1 is a signaling chain that includes microRNA-22 and the gene KDM3A. By targeting these links, researchers hope to break this cancer-causing chain.

Released: 28-Jan-2014 4:00 PM EST
“Weeding the Garden” with Radiation Allows ALK+ Lung Cancer Patients to Continue Crizotinib, Increasing Survival
University of Colorado Cancer Center

Study: patients taking crizotinib for ALK+ non-small cell lung cancer may safely and durably use up to three courses of targeted radiation therapy to eradicate pockets of drug-resistant disease.

Released: 29-Jan-2014 11:00 AM EST
Lung and Bladder Cancers Have Common Cell-Cycle Biomarkers
University of Colorado Cancer Center

CU Cancer Center study: bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle, with diagnostic, prognostic and treatment implications.

Released: 4-Feb-2014 2:00 PM EST
3D Mapping Biopsy Finds 3x Prostate Cancer of Ultrasound-Guided Biopsy
University of Colorado Cancer Center

University of Colorado Cancer Center study shows common locations of prostate cancers missed by ultrasound-guided biopsy.

Released: 11-Feb-2014 11:00 AM EST
Study: Resilience in Parents of Children Undergoing Stem Cell Transplant
University of Colorado Cancer Center

After a child’s stem cell transplant, parents feel increased distress at the time of the procedure, but eventually recover to normal levels of adjustment.

Released: 12-Feb-2014 11:00 AM EST
Study Highlights Long-Term Effects of Childhood Obesity on Late-Life Health
University of Colorado Cancer Center

"It may be that childhood obesity changes the way the whole metabolism is working – and changes it during a critical developmental time frame,” says Kristen Nadeau, MD, investigator at the University of Colorado Cancer Center.

Released: 13-Feb-2014 9:00 AM EST
Beauty Not Disease Motivates Teens to Wear Sunscreen
University of Colorado Cancer Center

"If our endgame is to modify their behavior, we need to tailor our message in the right way and in this case the right way is by highlighting consequences to appearance rather than health," says April W. Armstrong, PhD, MPH.

Released: 18-Feb-2014 12:00 PM EST
COXEN Model Picks the Best Drug for Ovarian Cancer
University of Colorado Cancer Center

University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.

Released: 21-May-2014 5:05 PM EDT
Big Data Lets Cancer Researchers Put Old Drugs to New Uses
University of Colorado Cancer Center

A study recently published in the journal Bioinformatics describes a new database and pattern-matching algorithm that allows researchers to evaluate rational drugs and drug combinations, and also recommends a new drug combination to treat drug-resistant non-small cell lung cancer.

30-May-2014 5:00 PM EDT
DREAM Project Crowdsources Answer to Cancer Cell Drug Sensitivities
University of Colorado Cancer Center

A study published June 1 in the journal Nature Biotechnology describes the results of an open challenge to predict which breast cancer cell lines will respond to which drugs, based only on the sum of cells’ genomic data.

30-May-2014 4:00 PM EDT
Oncologists: How to Talk With Your Pathologist About Cancer Molecular Testing
University of Colorado Cancer Center

An education session presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 details the challenges of collaboration between oncologists and pathologists in the context of molecular testing patient tumor samples.

30-May-2014 4:00 PM EDT
Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
University of Colorado Cancer Center

A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).

30-May-2014 4:00 PM EDT
ALK, ROS1 and now NTRK1: Study Shows Prevalence of New Genetic Driver in Lung Cancer
University of Colorado Cancer Center

A University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) draws a line from mutation of the gene NTRK1, to its role as an oncogene in non-small cell lung cancer, to treatment that targets this mutation.

30-May-2014 4:00 PM EDT
Study Shows Tale of Two Prognoses in Pediatric Brain Tumor, Pilocytic Astrocytoma
University of Colorado Cancer Center

Research presented at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 used a newly designed test for K:B fusion to show that point mutations lead to a more dangerous form of the disease than does K:B fusion.

30-May-2014 4:00 PM EDT
One Step Closer to a Breath Test for Lung Cancer
University of Colorado Cancer Center

Results of a University of Colorado Cancer Center study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) show that a test of organic compounds in exhaled breath can not only distinguish patients with lung cancer from patients with chronic obstructive pulmonary disease (COPD), but can also define the stage of any cancer present.

30-May-2014 4:00 PM EDT
Results in Phase I Trial of OMP-54F28, a Wnt Inhibitor Targeting Cancer Stem Cells
University of Colorado Cancer Center

At the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), University of Colorado Cancer Center researchers reported results of a Phase I trial of OMP-54F28 (FZD8-Fc), an investigational drug candidate discovered by OncoMed Pharmaceuticals targeting cancer stem cells (CSCs).

30-May-2014 4:00 PM EDT
Stopping Statins May Benefit Terminally Ill Patients
University of Colorado Cancer Center

Results presented today at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) and June 6 at the European Association of Palliative Care Research Conference show that stopping statins for cholesterol management in the late stages of cancer or other terminal illnesses may offer quality-of-life and even life-extending benefits.

Released: 30-May-2014 4:50 PM EDT
Results of Phase I Study of DMOT4039A, an Antibody-Drug Conjugate, in Patients with Pancreatic or Ovarian Cancer
University of Colorado Cancer Center

A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.

Released: 9-Jul-2014 11:05 AM EDT
Study of Dermatology on YouTube Shows New Ways Science Reaches Public
University of Colorado Cancer Center

A University of Colorado Cancer Center study published in the Dermatology Online Journal shows that YouTube also allows researchers, journals, and health advocates to connect directly with the public on topics of skin cancer and prevention.

Released: 15-Jul-2014 11:00 AM EDT
4 Lessons for Effective, Efficient Research in Health Care Settings
University of Colorado Cancer Center

University of Colorado Cancer Center study shows that by taking into account the real-world constraints of the systems in which providers deliver care and patients receive it, researchers can help speed results, cut costs, and increase chances that recommendations from their findings will be implemented.

Released: 5-Aug-2014 2:00 PM EDT
“Treatments Waiting to Be Discovered” Inside New Database
University of Colorado Cancer Center

A University of Colorado Cancer Center study recently published in Nucleic Acids Research describes a database named multiMiR, the most comprehensive database collecting information about microRNAs and their targets.

Released: 13-Aug-2014 2:00 PM EDT
National Clinical Trial Tests Power of COXEN Model to Predict Best Treatment for Bladder Cancer
University of Colorado Cancer Center

Computer model, COXEN, matches cancer genetics to best treatment. Currently in national clinical trial in bladder cancer.

Released: 22-Aug-2014 11:00 AM EDT
Online Screening for Rare Lung Cancer Mutation Opens Door to New Kind of Clinical Trial
University of Colorado Cancer Center

Cancer subtypes are like rare diseases; a new kind of clinical trial uses Dr. Google to find enough needles in enough haystacks to test drug ponatinib against FGFR positive lung cancer.

Released: 30-Sep-2014 11:00 AM EDT
NEJM: Crizotinib Effective in Phase 1 Trial Against ROS1 Lung Cancer
University of Colorado Cancer Center

University of Colorado Cancer Center researchers report 72 percent response rate with 19.2 month progression-free survival.

Released: 15-Oct-2014 5:00 PM EDT
Ebola Highlights Disparity of Disease Burden in Developed vs. Developing Countries
University of Colorado Cancer Center

Study highlights need to monitor disease in developing countries even when burden of diseases is low.


close
1.0235